Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that is newly diagnosed or has come back (relapsed) or not responded (refractory).
- Your leukemia test shows either an NPM1 mutation or a KMT2A rearrangement.
- Your overall health ability to function day-to-day is ECOG 0, 1, or 2 (meaning you’re able to do self-care and light activity).
- Your heart, kidney, and liver tests meet the study’s required levels.
- You cannot be pregnant or breastfeeding, and you must follow strict birth-control rules during the study and for 180 days after the last dose (or special extra rules if receiving quizartinib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.